SARS-CoV-2 Pseudovirus, KP.3.1.1 variant

Comprehensive Neutralization Assay Solutions for Advancing COVID-19 Research

Get your pseudovirus

KP.3.1.1 variant Advantages

This pseudovirus is pseudotyped with the Spike Glycoprotein of SARS-CoV-2 virus, KP.3.1.1 variant (GISAID Accession Number: EPI_ISL_19272251). This pseudovirus carries a modified genome that expresses a luciferase reporter gene (GFP on request).

Up to 1,000 reactions per mL (96-well plate)

Get a signal-to-background ratio of ≥10³ with 1 µL per well

Infectious titer of at least 10⁵ RLU/µL

The transduction efficiency is evaluated using HEK293 ACE2⁺ cells.

Lot to lot functionally validated

Infectivity and neutralization are evaluated for each batch

Lead Time: 2 - 3 week

We provide you with freshly produced pseudoviruses

QC report Order Now

Features

Enable specific detection

Expression of Spike glycoprotein, from KP.3.1.1 variant, as the sole surface antigen

Enhanced safety

Our pseudoviruses use a 3rd-generation lentivirus core and must be handled in BSL-2 conditions

Characterization of thermal stability

Stable at least 6 month at -80 °C

Support high-throughput screening

QC report Order Now

Applications

Pseudoviruses provide a safe and versatile platform for SARS-CoV-2 virus research and the development of therapeutic countermeasures. SARS-CoV-2 pseudoviruses have several important applications in research and development, including:

Vaccine Development

They are used to test the efficacy of new vaccines by evaluating their ability to induce neutralizing immune responses without the need for live pathogenic viruses.

Neutralizing Monoclonal Antibody Screening

Pseudoviruses enable rapid and safe screening of monoclonal antibodies targeting specific strains of the SARS-CoV-2 virus.

Antiviral Resistance Studies

They help study viral mutations and evaluate how these mutations affect sensitivity to antiviral treatments.

Fundamental Research on Viral Entry

Pseudoviruses are used to understand the mechanisms of viral entry into host cells, which is crucial for developing new therapies targeting these processes.

Treatment Efficacy Testing

They allow for the quick assessment of new antiviral agents’ effectiveness in controlled environments without the risks associated with highly pathogenic viruses.

QR reports Order Now

KP.3.1.1 Variant's Background

The SARS-CoV-2 Omicron variant KP.3.1.1 is an emerging sublineage of the JN.1 lineage that has shown increasing global circulation since 2024. It belongs to the rapidly evolving Omicron family, which continues to drive COVID-19 transmission worldwide (WHO).

KP.3.1.1 carries additional mutations in the spike protein, including changes in the receptor-binding domain (RBD) such as L455S, which are associated with enhanced viral fitness and immune escape (Nature Communications). These mutations may affect antibody recognition and contribute to reduced neutralization by prior immunity.

Compared with earlier Omicron subvariants, KP.3.1.1 demonstrates a growth advantage and increased transmissibility, supporting its rapid spread in multiple regions (The Lancet Infectious Diseases). In vitro studies also suggest increased infectivity and reduced neutralization sensitivity (Cell Reports).

Despite its immune evasion properties, there is currently no evidence of increased disease severity. However, its continued evolution highlights the importance of genomic surveillance, updated COVID-19 vaccines, and booster strategies to limit the impact of emerging SARS-CoV-2 variants.

SARS-CoV-2 pseudovirus, KP.3.1.1 in Publications

The emergence and global spread of the SARS-CoV-2, KP.3.1.1 variant, characterized by increased transmissibility and partial immune escape, underscored the need for effective vaccines and antiviral strategies against evolving viral strains. By eliminating the need to handle infectious BSL-3 virus, pseudovirus neutralization assays offer a safe, rapid, scalable, and standardized platform for evaluating neutralizing monoclonal antibodies (mAbs) and antiviral compounds targeting the spike (S) protein of SARS-CoV-2 variants.

Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants

 

Order Now

Documentation

Quality control reports

Access QR reports

SDS

Access SDS

×

Get your document

Fill out the form below to get your document

"*" indicates required fields

Name*

First Last

Email*

This field is hidden when viewing the form

Document URL